JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety
Clinical trial NCT04874844 · UNKNOWN
Trial details
- NCT number
- NCT04874844
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-30
- Primary completion
- 2022-03-30
- Enrollment
- 420
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.